Good Fellow Healthcare Holdings Limited (Stock Code: 8143) reported its unaudited interim results for the six months ended 30 September 2025. During the period under review, revenue stood at approximately HK$10.500 million, a level similar to about HK$10.435 million in the same period last year. Gross profit margin rose slightly to about 79.37% compared to around 78.40% in the corresponding period of 2024.
The company recorded a loss attributable to owners of the Company of about HK$2.671 million, compared to a profit of roughly HK$7.602 million in the previous year. The main reason for the turnaround from profit to loss was the absence of a one-off gain from the disposal of subsidiaries, which amounted to approximately HK$10.458 million in the earlier period. The board does not recommend the payment of any interim dividend.
The general hospital services business remained the key activity, generating turnover of approximately HK$10.500 million. During the reporting period, the group noted evolving healthcare demand in China and highlighted that intensified competition in certain metropolitan areas, along with changes in regulatory requirements, prompted a strategic review of existing operations in Beijing. Resources are being refocused on potential growth regions, particularly in Hainan Province, where the company anticipates advantages for high-quality specialty medical services.
The group signed lease agreements for hospital premises and medical facility space in the Hainan Pilot Zone. Subject to approval processes in accordance with relevant regulations, it expects to further develop and operate a Grade III specialised hospital in Hainan. Preparatory efforts also include the appointment of a dedicated hospital chief executive to support forthcoming regulatory and operational requirements. Meanwhile, the group plans to enhance healthcare management and digital-health cooperation projects to maintain a stable revenue base.
As at 30 September 2025, the company reported total cash and cash equivalents of approximately HK$7.519 million, up from about HK$3.829 million at the end of March 2025. Overall current assets stood at around HK$19.183 million, while current liabilities amounted to approximately HK$1.868 million, leading to a current ratio of roughly 9.26. The board maintained a cautious outlook, noting continued attention to regulatory shifts and macroeconomic factors, and reaffirmed a commitment to prudent resource allocation and disciplined management.